What is Phenomix Sciences?
Phenomix Sciences specializes in the transformative field of precision obesity medicine, leveraging artificial intelligence to analyze complex patient data. Their proprietary MyPhenome Test integrates genetic predispositions, clinical health records, and specific biomarker information to provide a deeply personalized understanding of an individual's obesity. This data-driven approach empowers healthcare providers to select the most effective and appropriate therapeutic interventions, moving beyond one-size-fits-all strategies. By focusing on the root causes of obesity, Phenomix aims to enhance patient compliance, reduce long-term healthcare costs, and significantly improve treatment efficacy. The company's innovative platform is at the forefront of personalized medicine, aiming to revolutionize how obesity is understood and managed.
How much funding has Phenomix Sciences raised?
Phenomix Sciences has raised a total of $7.8M across 2 funding rounds:
Grant
$2.3M
Series A
$5.5M
Grant (2024): $2.3M with participation from National Institutes of Health
Series A (2024): $5.5M led by Health2047, Labcorp, and Dexcom
Key Investors in Phenomix Sciences
National Institutes of Health
The National Institutes of Health (NIH) is a primary agency of the U.S. Department of Health and Human Services, responsible for biomedical and health-related research, indicating a focus on foundational scientific advancement and public health initiatives.
Health2047
Health2047, powered by the American Medical Association, is a venture studio focused on transforming healthcare by founding, funding, and scaling companies that enhance diagnostics and improve care delivery, suggesting a strategic interest in innovative healthcare solutions.
Labcorp
Labcorp is a leading laboratory services company providing vital diagnostic information for healthcare decisions, indicating a strong interest in companies that can leverage diagnostic data for improved patient outcomes and clinical insights.
What's next for Phenomix Sciences?
With the recent influx of major enterprise-level funding and a strategic investment, Phenomix Sciences is well-positioned for significant growth and market expansion. This capital infusion is expected to fuel further research and development, enhance their AI capabilities, and broaden the reach of the MyPhenome Test to a wider clinical audience. The company's strategic focus on integrating diverse data streams for personalized obesity treatment places it in a strong competitive position within the rapidly evolving healthcare technology sector. Future developments will likely involve expanding partnerships with healthcare systems and pharmaceutical companies, further solidifying their role in advancing precision medicine for metabolic health.
See full Phenomix Sciences company page
